Actively Recruiting
Phase 4 Multicenter Study of Oral Surufatinib for Adults With Advanced Neuroendocrine Tumors
Led by Shanghai Zhongshan Hospital · Updated on 2025-12-19
350
Participants Needed
4
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of surufatinib in adults with advanced neuroendocrine neoplasms NENs in a prospective, multicenter, phase 4, single-arm study. Surufatinib is an oral drug with anti-angiogenic and immune-modulating effects, previously shown to have meaningful clinical activity. This study aims to gather real-world evidence on surufatinibs use, safety, and impact on quality of life in patients with confirmed advanced NENs who have measurable disease. Participants will receive surufatinib orally either as monotherapy 300 mg once daily in continuous 4-week cycles or in combination regimens 250 mg once daily based on the treating physicians judgment and study guidelines. Treatment continues until disease progression, unacceptable side effects, withdrawal, death, or study end. The study allows dose adjustments and use of other anticancer therapies as needed. Follow-up includes regular imaging, lab tests, cardiac monitoring, and patient questionnaires. During the study, researchers will assess tumor response, side effects, quality of life, and treatment adherence. Key outcomes measured include progression-free survival, objective response rate, disease control rate, and overall survival. Safety is monitored through adverse event tracking. Patients will be followed for up to 36 months to collect these data and to help guide future individualized treatment strategies with surufatinib in real-world clinical practice.
CONDITIONS
Brief Title
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Research Team
W
Wenquan Wang, M.D. Ph.D
X
Xu Han, M.D. Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here